Adjuvant antineoplastics +/- darbepoetin alfa in women with node-positive breast cancer

Trial Profile

Adjuvant antineoplastics +/- darbepoetin alfa in women with node-positive breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms WSG-ARA Plus
  • Most Recent Events

    • 01 Jan 2014 Status changed from active, no longer recruiting to completed according to results published in the Annals of Oncology.
    • 05 Jan 2012 New trial record
    • 10 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top